WLWT: UC hosts RESET epilepsy trial
WLWT recently highlighted the RESET study, a trial at the University of Cincinnati that will study a new treatment for the most severe and deadly form of epilepsy.
Brandon Foreman, MD, site principal investigator at UC for the trial being conducted across approximately 50 hospital emergency departments across the country, told WLWT the study focuses on a condition called status epilepticus (SE).
"About 10 percent of the folks who have seizures, when they come into the emergency department, are having status epilepticus," said Foreman, associate professor and associate director of neurocritical care research in the Department of Neurology and Rehabilitation Medicine in UC’s College of Medicine and a UC Health physician. SE is a disorder Foreman described as "seizures that don't stop."
The trial will test a new drug, ganaxolone, a neurosteroid your brain produces that can help stop seizures that won't end on their own.
"So, the promise with this medication is if you're still having seizures, despite that kind of class, one level of evidence medication...that we can give this medication and it sort of fits in at that point. Hopefully, we'll stop the seizures," Foreman said.
Featured photo at top of ambulance. Photo/Camilo Jimenez/Unsplash.
Related Stories
UC graduates cross finish line at commencement
August 7, 2026
The University of Cincinnati recognized 2,125 graduates in two ceremonies at summer commencement Friday on campus at Fifth Third Arena.
Co-op students survey fish to track stream restoration
August 7, 2026
A fish survey at the University of Cincinnati is showing how efforts to restore urban waterways are working to bring back aquatic life.
Bidirectional link between oral, kidney health calls for patient education, access
August 4, 2026
Despite growing awareness of the connection between oral health and chronic health conditions, patient awareness and access to dental care remain limited, according to University of Cincinnati experts who recently spoke with Healio | Nephrology News & Issues.